{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:36:06Z","timestamp":1773970566416,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0955"],"award-info":[{"award-number":["W81XWH-21-1-0955"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.adro.2025.101936","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T11:09:58Z","timestamp":1761649798000},"page":"101936","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Natural History and Risk Stratification of Biochemically Recurrent Prostate Cancer Following Definitive Radiation Therapy"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7966-3090","authenticated-orcid":false,"given":"Paul","family":"Riviere","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kylie M.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Sabater","family":"Minarim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah","family":"Deshler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew P.","family":"Banegas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler F.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Javier-DesLoges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Kellogg","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent S.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2025.101936_bib0001","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0039","article-title":"Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: The NRG oncology RTOG 0126 randomized clinical trial","volume":"4","author":"Michalski","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.adro.2025.101936_bib0002","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): Outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2025.101936_bib0003","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ijrobp.2019.02.045","article-title":"Dose escalation for prostate adenocarcinoma: A long-term update on the outcomes of a phase 3, single institution randomized clinical trial","volume":"104","author":"Pasalic","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2025.101936_bib0004","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.eururo.2014.09.028","article-title":"The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy","volume":"67","author":"Zumsteg","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.adro.2025.101936_bib0005","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1200\/JCO.23.00617","article-title":"Biochemical recurrence surrogacy for clinical outcomes after radiotherapy for adenocarcinoma of the prostate","volume":"41","author":"Roy","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2025.101936_bib0006","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.adro.2025.101936_bib0007","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/jnci\/djg043","article-title":"Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy","volume":"95","author":"D'Amico","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.adro.2025.101936_bib0008","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","article-title":"Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: A systematic review","volume":"75","author":"Van den Broeck","year":"2019","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.adro.2025.101936_bib0009","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: Screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.adro.2025.101936_bib0010","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2025.101936_bib0011","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1200\/CCI.21.00030","article-title":"Ascertainment of veterans with metastatic prostate cancer in electronic health records: Demonstrating the case for natural language processing","volume":"5","author":"Alba","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.adro.2025.101936_bib0012","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2016.5983","article-title":"Surrogate end points for all-cause mortality in men with localized unfavorable-risk prostate cancer treated with radiation therapy vs radiation therapy plus androgen deprivation therapy: A secondary analysis of a randomized clinical trial","volume":"3","author":"Royce","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.adro.2025.101936_bib0013","series-title":"Statistics for Biology and Health","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/978-1-4614-1353-0","article-title":"Regression methods in biostatistics: Linear, logistic, survival, and repeated measures models","author":"Vittinghoff","year":"2012"},{"key":"10.1016\/j.adro.2025.101936_bib0014","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1200\/JCO.23.02410","article-title":"Delaying prostate-specific antigen progression in biochemically recurrent prostate cancer: Is it clinically meaningful?","volume":"42","author":"Childs","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2025.101936_bib0015","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.23.01157","article-title":"PRESTO: A phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19)","volume":"42","author":"Aggarwal","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2025.101936_bib0016","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/cncr.23161","article-title":"Cancer of the Prostate Strategic Urological Research Endeavor. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes","volume":"112","author":"Agarwal","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2025.101936_bib0017","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1002\/cncr.10977","article-title":"Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above","volume":"95","author":"Kupelian","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2025.101936_bib0018","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1200\/JCO.2016.67.9647","article-title":"Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy","volume":"34","author":"Tendulkar","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2025.101936_bib0019","doi-asserted-by":"crossref","first-page":"298.e1","DOI":"10.1016\/j.urolonc.2020.12.023","article-title":"Validation of the European Association of Urology biochemical recurrence risk groups after radical prostatectomy in an Asian cohort and suggestions for refinement","volume":"39","author":"Pak","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.adro.2025.101936_bib0020","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.eururo.2019.03.016","article-title":"External validation of the European Association of Urology biochemical recurrence risk groups to predict metastasis and mortality after radical prostatectomy in a European cohort","volume":"75","author":"Tilki","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.adro.2025.101936_bib0021","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): A randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2025.101936_bib0022","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.adro.2025.101936_bib0023","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER)","volume":"80","author":"Valle","year":"2021","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.adro.2025.101936_bib0024","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.15911","article-title":"Androgen deprivation therapy and outcomes after radiation therapy in black patients with prostate cancer","volume":"7","author":"Morgan","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.adro.2025.101936_bib0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.39769","article-title":"Comparison of response to definitive radiotherapy for localized prostate cancer in black and white men: A meta-analysis","volume":"4","author":"Ma","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.adro.2025.101936_bib0026","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2025.101936_bib0027","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2967\/jnumed.121.262821","article-title":"PSMA PET validates higher rates of metastatic disease for European Association of Urology biochemical recurrence risk groups: An international multicenter study","volume":"63","author":"Ferdinandus","year":"2022","journal-title":"J Nucl Med"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109425002234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109425002234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:02:49Z","timestamp":1773964969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109425002234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2452109425002234"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2025.101936","relation":{},"ISSN":["2452-1094"],"issn-type":[{"value":"2452-1094","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural History and Risk Stratification of Biochemically Recurrent Prostate Cancer Following Definitive Radiation Therapy","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2025.101936","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101936"}}